Archives
-
Gut Microbial H2S Suppresses GLP-1 in Male Mice
2026-08-31
The reference study identifies Desulfovibrio-derived hydrogen sulfide as a gut-to-host metabolic signal that suppresses GLP-1 production in male mice. By linking microbial H2S to impaired mitochondrial respiration and the unfolded protein response in intestinal L cells, the work provides a mechanistic framework for how dysbiosis may contribute to metabolic syndrome and shows that bismuth subsalicylate can improve metabolic outcomes in the tested models.
-
hiPSC Intestinal Organoids for Pharmacokinetic Studies
2026-08-31
Saito and colleagues developed a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The organoids could be propagated, cryopreserved, and converted into epithelial monolayers containing enterocytes with cytochrome P450 and transporter activities, creating a more human-relevant platform for pharmacokinetic studies.
-
Lipo3K Transfection Reagent for PTX-Resistance Studies
2026-08-30
Use Lipo3K Transfection Reagent to build reproducible DNA, siRNA, mRNA, and co-transfection workflows in resistant breast cancer models. Its low-toxicity cationic lipid chemistry is particularly useful when transporter perturbation, drug accumulation, and cell viability must be measured in the same experiment.
-
2-NBDG Glucose Uptake Assay Kit for HCC
2026-08-29
The 2-NBDG Glucose Uptake Assay Kit adds a direct, non-radioactive glucose-transport readout to hepatocellular carcinoma research. This article explains how to use uptake phenotyping alongside the HNF4A-AS1–lipid metabolism findings without overstating what the assay can prove.
-
Angiotensin (1-7): Mechanism to Translation
2026-08-28
A translational framework for using Angiotensin (1-7), Asp-Arg-Val-Tyr-Ile-His-Pro, as a sequence-defined probe of ACE2–Mas biology, pathway regulation, tissue protection, and model selection.
-
Cefazedone–Etimicin PK by UFLC–MS/MS
2026-08-28
The reference study developed and validated a rapid UFLC–MS/MS assay for simultaneous measurement of cefazedone and etimicin in beagle dog plasma. Its application to intravenous dosing found no obvious pharmacokinetic difference between combination treatment and either antibiotic administered alone, providing a useful analytical basis for evaluating coadministration.
-
Resiniferatoxin (RTX) Workflows for Pain Research
2026-08-27
Resiniferatoxin (RTX) converts TRPV1 activation into a precise research strategy for silencing nociceptive signaling in osteoarthritis, neuropathic pain, and neurogenic inflammation models. This guide covers assay setup, route-specific study design, calcium-imaging workflows, and troubleshooting for reproducible sensory-neuron desensitization.
-
AG-490: JAK2/EGFR Inhibition in Cell Assays
2026-08-27
This scenario-based guide explains how AG-490 (JAK2/EGFR inhibitor), SKU A4139, can help researchers distinguish pathway-dependent growth suppression from nonspecific assay effects. It covers concentration selection, solvent compatibility, viability workflow design, signaling interpretation, and practical vendor evaluation.
-
Topotecan Assay Workflows for Cancer Research
2026-08-26
Build reproducible Topotecan and SKF104864 workflows that connect viability, DNA damage, apoptosis, and cell-cycle phenotypes. The guide adapts a multiplexed pathway-analysis strategy from HPV research while focusing on glioma, combination treatment, and pediatric tumor-model applications.
-
Annexin V-FITC/7-AAD Apoptosis Kit Guide
2026-08-26
The Annexin V-FITC/7-AAD Apoptosis Kit provides a rapid dual-fluorescence method for separating viable, early apoptotic, and membrane-compromised cell populations in cell viability and cytotoxicity workflows. It is intended for intact cells analyzed by fluorescence microscopy or flow cytometry, not as a standalone proof of apoptotic mechanism or a clinical diagnostic test.
-
Dacomitinib: From ErbB Blockade to Ferroptosis Assays
2026-08-25
Explore how Dacomitinib and PF-00299804 can be used to dissect ErbB signaling, apoptosis, and mitochondrial ferroptosis susceptibility. This article translates METTL17 findings into a practical assay strategy while clearly separating established evidence from exploratory hypotheses.
-
Resazurin Sodium Salt in iPSC-CF Testing
2026-08-25
Patient-derived iPSC airway models are making cystic fibrosis drug testing more genotype-aware, but translational decisions require both disease-specific functional measurements and robust cell-state controls. This article positions Resazurin sodium salt as a complementary redox-based readout for viability, metabolic activity, assay quality, and screening scalability—not as a substitute for direct CFTR function assays.
-
11β-HSD1 Inhibition, Notch, and NK Cells in Fibrosis
2026-08-24
A 2025 mouse study identifies a dual immunometabolic mechanism by which 11β-HSD1 inhibition reduces thioacetamide-induced liver fibrosis. The work links lower intrahepatic cortisol to suppression of Notch signaling and enhanced natural killer cell-mediated clearance of activated hepatic stellate cells, offering a mechanistic framework for liver fibrosis research.
-
Hypoxia, S100A10, and GBM Chemoresistance
2026-08-24
The reference study identifies hypoxia-induced S100A10 as a driver of glioblastoma proliferation, glycolytic activity, apoptosis suppression, and temozolomide resistance through PI3K–AKT signaling. Its integrative use of public datasets, molecular assays, metabolic measurements, and cell-death analysis provides a framework for connecting tumor microenvironmental stress with treatment failure.
-
DNA Frameworks Improve Enzymatic Oligonucleotide Synthesis
2026-08-23
The reference study introduces tetrahedral DNA nanostructures as an ordered interface that improves primer presentation, enzyme accessibility, and reaction performance in enzymatic oligonucleotide synthesis. Its TDN-based system reduced deletion errors in patterned sequences and achieved a reported 96.82% stepwise yield while encoding 15 bytes of text in a 60-nucleotide DNA fragment.